RANI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rani Therapeutics Holdings Inc (RANI) is not a strong buy for a beginner investor with a long-term strategy at this moment. The stock shows a bearish technical trend, limited positive catalysts, and lacks strong trading signals. While the company has shown revenue growth, its financials remain weak with negative net income and declining EPS. Analysts have lowered the price target, and there are no significant recent events or news to drive a strong upward movement in the near term.
The technical indicators are mixed to bearish. The MACD is positive and expanding, but the RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key resistance levels, with a pivot at 0.844 and resistance at 0.951 and 1.017.
Revenue increased by 42.12% YoY in Q4 2025, and the company initiated a Phase I clinical study for RT-114, which could be a long-term growth driver.
Net income remains negative at -$10.3M, and EPS dropped significantly by -74.07% YoY. Analysts lowered the price target from $9 to $5, reflecting reduced confidence in the stock's near-term performance. No significant trading trends from hedge funds or insiders.
In Q4 2025, revenue increased to $1.46M (up 42.12% YoY), but net income remained negative at -$10.3M (up 15.18% YoY). EPS dropped to -0.07 (down -74.07% YoY), and gross margin remained flat at 100%.
Canaccord lowered the price target from $9 to $5 while maintaining a Buy rating. The firm updated its model after the company reported financial results and initiated a Phase I clinical study for RT-114, with data expected in 2H26.
